Q1 2025 Orchid Pharma Ltd Earnings Call Transcript
Key Points
- Orchid Pharma Ltd (BOM:524372) reported a robust 34% increase in sales for Q1 FY25, reaching INR244 crores compared to INR182.9 crores in the same period last year.
- The company's EBITDA for Q1 FY25 saw a substantial increase of 71%, amounting to INR41 crores compared to INR24 crores in Q1 FY24.
- Employee expenses remained steady at 8.7% of sales in Q1 FY25, showing effective cost control.
- Orchid Pharma Ltd (BOM:524372) is set to launch Orblices, a new product in partnership with Cipla, which is expected to have a significant market impact.
- The company has completed land acquisition for its 7ACA project and plans to break ground soon, indicating progress in its expansion plans.
- Despite the strong financial performance, the company faces increased competition in the cephalosporin market, which could impact future growth.
- The US market remains uncertain due to FDA issues faced by one of Orchid Pharma Ltd (BOM:524372)'s main customers, affecting API sales.
- The company's new sterile block is currently only at 50% utilization and is limited to emerging markets until further regulatory approvals are obtained.
- The expected sales from the Enmetazobactam product in the US and China markets remain unclear, with no new developments reported.
- The merger with Dhanuka is still pending regulatory approval, creating uncertainty about the timeline for completion.
Ladies and gentlemen, good day, and welcome to the Orchid Pharma Limited Q1 FY25 earnings conference call hosted by Systematix Institutional Equities. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Vishal Manchanda from Systematix Institutional Equities. Over to you, sir.
()-
Thank you, Deepika. Good evening, everyone. On behalf of Systematix Institutional Equities, I welcome you to the Q1 FY25 earnings call of Orchid Pharma.
We thank the Orchid Pharma management for giving us an opportunity to host the call today. We have with us the senior management of the company represented by Mr. Manish Dhanuka, Managing Director; Mr. Mridul Dhanuka, Whole Time Director; and Mr. Sunil Kumar Gupta, Chief Financial Officer.
I now hand over the call to the management for opening remarks. Over to you, sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
